Monoclonal antibody strategies to block angiogenesis

Related Experiment Video

Updated: Oct 7, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

D J. Hicklin1, L Witte, Z Zhu

  • 1ImClone Systems, 180 Varick Street, 10014, New York, NY, USA

Drug Discovery Today
|May 23, 2001
PubMed

Insights

Antibody therapeutics show promise for treating diseases like cancer by targeting new blood vessel formation (angiogenesis). This review focuses on antibody-based strategies and pre-clinical data for inhibiting angiogenesis.

Area of Science:

  • Immunology and Oncology
  • Therapeutic Antibody Development

Background:

  • Antibodies are highly specific therapeutics with increasing clinical success in cancer treatment.
  • Angiogenesis, or new blood vessel formation, is a key process in diseases like cancer.
  • Antibody therapeutics present a promising strategy for targeting angiogenesis.

Purpose of the Study:

  • To review antibody-based therapeutics targeting angiogenesis.
  • To focus on angiogenesis-related mechanisms.
  • To emphasize pre-clinical in vivo data.

Main Methods:

  • Literature review of antibody-based angiogenesis inhibitors.
  • Analysis of pre-clinical in vivo studies.
  • Focus on mechanisms of action.

Main Results:

  • Antibodies can effectively target key pathways in angiogenesis.
  • Pre-clinical data supports the efficacy of various antibody-based strategies.
  • Specific examples of antibody targets in angiogenesis are discussed.

Conclusions:

  • Antibody therapeutics are a viable and developing approach for anti-angiogenesis therapy.
  • Further research and clinical development are warranted.
  • Pre-clinical in vivo data is crucial for validating these therapeutic strategies.

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...